CXCR4 and Miyoshi myopathy: Additionally, the PET tracer targeting CXCR4 (68Ga-CXCR4) has been evaluated in MM patients, showing that CXCR4 expression is typically observed in advanced stages of MM, and is regarded as an adverse prognostic marker, given its association with aggressive disease and poor outcomes [46,47,48].